High ionized calcium levels were associated with an increased risk for hyperparathyroidism, especially among men.
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Corporate Updates: In January 2025, Septerna appointed Gil Labrucherie, CFA, J.D., as chief financial officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior ...
A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...
How well do injection protocols affect the progression of osteoporosis in bone? A new study from a group of Swiss researchers ...
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback